Gut microbiome as a biomarker for predicting early recurrence of HBV ‐related hepatocellular carcinoma
Cancer Science · 2023-12 · 114 (12) · 4717-4731
DOI: 10.1111/cas.15983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023-10. Verfasst von Chongming Zheng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Gastrointestinal Microbiome, Liver Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
To investigate the potential of the gut microbiome as a biomarker for predicting the early recurrence of HBV‐related hepatocellular carcinoma (HCC), we enrolled 124 patients diagnosed with HBV‐associated HCC and 82 HBV‐related hepatitis, and 86 healthy volunteers in our study, collecting 292 stool samples for 16S rRNA sequencing and 35 tumor tissue samples for targeted metabolomics. We performed an integrated bioinformatics analysis of gut microbiome and tissue metabolome data to explore the gut microbial–liver metabolite axis associated with the early recurrence of HCC. We constructed a predictive model based on the gut microbiota and validated its efficacy in the temporal validation cohort. Dialister , Veillonella , the Eubacterium coprostanoligenes group, and Lactobacillus genera, as well as the Streptococcus pneumoniae and Bifidobacterium faecale species, were associated with an early recurrence of HCC. We also found that 23 metabolites, including acetic acid, glutamate, and arachidonic acid, were associated with the early recurrence of HCC. A comprehensive analysis of the gut microbiome and tissue metabolome revealed that the entry of gut microbe‐derived acetic acid into the liver to supply energy for tumor growth and proliferation may be a potential mechanism for the recurrence of HCC mediated by gut microbe. We constructed a nomogram to predict early recurrence by combining differential microbial species and clinical indicators, achieving an AUC of 78.0%. Our study suggested that gut microbes may serve as effective biomarkers for predicting early recurrence of HCC, and the gut microbial–tumor metabolite axis may explain the potential mechanism by which gut microbes promote the early recurrence of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Hepatobiliary Pancreatic Tumor Bioengineering Cross International Joint Laboratory of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Wenzhou Medical University, Wenzhou, China.
- Department of Epidemiology and Biostatistics, School of Public Health and Management, Wenzhou Medical University, Wenzhou, China.
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- The First Affiliated Hospital of Wenzhou Medical University, Zhejiang-Germany Interdisciplinary Joint Laboratory of Hepatobiliary-Pancreatic Tumor and Bioengineering, Wenzhou, China.
ORCID-Profile: Zhiyuan Bo, Yi Wang, Gang Chen
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Zheng, C., Lu, F., Chen, B., Yang, J., Yu, H., Wang, D., Xie, H., Chen, K., Xie, Y., Li, J., Bo, Z., Wang, Y., Chen, G., & Deng, T. (2023). Gut microbiome as a biomarker for predicting early recurrence of HBV ‐related hepatocellular carcinoma. Cancer Science, 114(12), 4717-4731. https://doi.org/10.1111/cas.15983
Vancouver
Zheng C, Lu F, Chen B, Yang J, Yu H, Wang D, et al. Gut microbiome as a biomarker for predicting early recurrence of HBV ‐related hepatocellular carcinoma. Cancer Science. 2023;114(12):4717-4731. doi:10.1111/cas.15983
BibTeX
@article{Zheng2023,
author = {Zheng, Chongming and Lu, Fei and Chen, Bo and Yang, Jinhuan and Yu, Haitao and Wang, Daojie and Xie, Haonan and Chen, Kaiwen and Xie, Yitong and Li, Jiacheng and Bo, Zhiyuan and Wang, Yi and Chen, Gang and Deng, Tuo},
title = {Gut microbiome as a biomarker for predicting early recurrence of HBV ‐related hepatocellular carcinoma},
journal = {Cancer Science},
year = {2023},
volume = {114},
number = {12},
pages = {4717--4731},
doi = {10.1111/cas.15983}
}
EUVIMED